Ceftolozane Tazobactam – Injection products
Recognized Interpretive Criteria
|
Minimum Inhibitory |
Disk Diffusion |
||||
---|---|---|---|---|---|---|
Pathogen |
S |
I |
R |
S |
I |
R |
Enterobacterales |
M-100 standard is recognized |
|||||
Pseudomonas aeruginosa |
M-100 standard is recognized |
|||||
Streptococcus spp Viridans |
M-100 standard is recognized |
- |
- |
- |
||
Bacteroides fragilis |
≤8/4 |
16/4 |
≥32/4 |
- |
- |
- |
Haemophilus influenzae |
M-100 standard is recognized |
- |
- |
- |
S = Susceptible; I = Intermediate; R = Resistant
STIC are based on a dose for adults of 1.5g every 8 h for the treatment of complicated intra-abdominal infections and complicated urinary tract infections or a dose of 3 g every 8 h for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.